Faron Pharmacueticals Oy's chief executive Dr Markku Jalkanen caught up with Proactive London after publishing half-year results.
As the company looks to develop its bexmarilimab antibody in the field of cancer immunotherapy, Jalkanen talks through the financial performance in the half, and the potential next steps for the drug.